Your search for Warfarin returned 18 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Drugs in the Pipeline remove

Your search for Warfarin returned 18 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

FDA to Review New Warfarin Formulation

Accu-Break Pharmaceuticals (ABP) announced that the Food & Drug Administration (FDA) has accepted for filling the New Drug Application (NDA) for Warfarin Potassium.
Drugs in the Pipeline

Dabigatran Comparable to Warfarin in DVT/PE Trial

Boehringer Ingelheim announced results from the RE-COVER II study evaluating dabigatran compared to warfarin in patients diagnosed with acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE).
Drugs in the Pipeline

Xarelto Safety, Efficacy for DVT Confirmed in Real-World Data

Janssen and Bayer announced the results from their real-world study XALIA, showing that the rates of major bleeding and recurrent blood clots for Xarelto (rivaroxaban) in routine clinical practice were generally consistent with Phase 3 data in patients with deep vein thrombosis (DVT), with shorter hospital stays than standard anticoagulation.
Drugs in the Pipeline

Results Announced for Eliquis in Nonvalvular Atrial Fibrillation Trial

Bristol-Myers Squibb and Pfizer announced results of a pre-specified subanalysis of the Phase 3 ARISTOTLE trial that assessed the effect of blood pressure control on outcomes as well as the treatment effect of Eliquis (apixaban) vs. warfarin to blood pressure control in patients with nonvalvular atrial fibrillation (NVAF).
Drugs in the Pipeline

Daiichi Sankyo Submits Savaysa NDA for Thromboembolic Disorders

Daiichi Sankyo has announced that a New Drug Application (NDA) has been submitted to the FDA for Savaysa (edoxaban) Tablets for the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF), as well as for the treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE) and for the prevention of recurrence of symptomatic venous thromboembolism (VTE).
Drugs in the Pipeline

FDA to Review Eliquis sNDA for DVT/PE Treatment

The FDA has accepted for review a Supplemental New Drug Application (sNDA) for Eliquis (apixaban; Bristol-Myers Squibb Company and Pfizer) for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE.